ClinicalTrialsFinder
CompletedPhase 3ACTRN12611000402943

Effect of Vitamin D Supplementation on Cardiovascular and Respiratory Disease Event Rates, and the incidence of fractures

Effect of Vitamin D Supplementation on Cardiovascular and Respiratory Disease Event Rates in Older Adults, and the incidence of non-vertebral fractures.

Sponsor

University of Auckland

Enrollment

5,110 participants

Start Date

Jun 3, 2011

Study Type

Interventional

Conditions

Non-vertebral fracturesCancerCardiovascular DiseaseRespiratory Disease

Summary

The main aims of the study are to see if vitamin D supplementation reduces the incidence rates of cardiovascular disease, respiratory disease and non-vertebral fractures.

Eligibility

Sex: Both males and femalesMin Age: 50 YearssMax Age: 84 Yearss

Plain Language Summary

Simplified for easier understanding

This large trial tests whether taking a daily vitamin D supplement can prevent cardiovascular disease, respiratory disease, and bone fractures in adults aged 50-84 living in Auckland, New Zealand. Participants must not already be taking high-dose vitamin D supplements and must not have conditions like kidney stones or high calcium levels.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Vitamin D3 (cholecalciferol) 200,000 IU oral capsule at baseline, then 100,000 IU oral capsule monthly for 4 years

Vitamin D3 (cholecalciferol) 200,000 IU oral capsule at baseline, then 100,000 IU oral capsule monthly for 4 years

Locations(1)

Auckland, New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611000402943

Related Trials

Patient-Centered Assessment of Symptoms and Outcomes

NCT039526241 location

Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention

NCT019277831 location

Tumor Related Epilepsy

NCT026393251 location

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

NCT055881411 location

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

NCT07136012243 locations